The US Food and Drug Administration (FDA) has published a safety communication that identifies Applied DNA Sciences’ Linea COVID-19 Assay Kit as one of only two tests marketed under its emergency use authorisation (EUA) to detect certain SARS-CoV-2 mutations.

The mutations include the one found in the UK variant of SARS-CoV-2 called B.1.1.7. It can potentially increase the transmission risk of the virus that causes Covid-19.

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

The detection of specific mutations can help in identifying samples that should be further characterised through genetic sequencing and can help to detect the new variants in patients early.

Authorised by FDA EUA, the kit is used for the qualitative detection of SARS-CoV-2 nucleic acid in respiratory samples such as anterior nasal swabs, nasopharyngeal and oropharyngeal swabs, mid-turbinate nasal swabs, and nasopharyngeal washes / aspirates or nasal aspirates.

In addition, it can test for the virus in bronchoalveolar lavage (BAL) specimens taken by a healthcare professional from people who are suspected of Covid-19 by a healthcare provider.

Applied DNA Sciences president and CEO Dr James Hayward said: “Our ability to potentially identify certain variants of SARS-CoV-2 is grounded in the multi-target design of our assay that mitigates the impact of a mutation to the S-gene on test sensitivity.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

“We believe our assay kit can give public health officials and diagnostic laboratories a fast and cost-efficient tool – whether through diagnostic or pooled surveillance testing – with which to potentially identify and track B.1.1.7 spread that is made all the more challenging by the variant’s apparent transmission advantage.”

Last month, Applied DNA Clinical Laboratories (ADCL), a wholly owned subsidiary of Applied DNA Sciences, entered a reseller and sales referral partnership with US-based health and safety solutions provider CLEARED4.

Medical Device Network Excellence Awards - Nominations Closed

Nominations are now closed for the Medical Device Network Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact

Excellence in Action
SC MEDICA’s minimally invasive, radiation free spinal facet fixation system, FFX® is transforming spinal pain management and improving outcomes for surgeons and patients alike. Learn how SC MEDICA’s award-winning technology is redefining standards in facet joint pain treatment.

Discover the Impact